Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer

Ivanović, Vesna; Melman, Arnold; Davis-Joseph, Brian; Valcic, Mira; Geliebter, Jan

doi:10.1038/nm0495-282

Cited by 161 publications

(71 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the course of investigations about the role of TGF-1 as a potential tumour-promoting factor, elevated TGF-1 I plasma levels have been detected in patients with invasive prostate cancer (Ivanovic et al, 1995). In a similar study, we previously found significantly elevated TGF-,B1 serum levels in patients with invasive bladder carcinomas (Eder et al, 1996).…”

supporting

confidence: 60%

Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas

Eder

Stenzl²,

Hobisch³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary We previously detected elevated transforming growth factor beta-1 (TGF-11) serum levels in patients with invasive bladder carcinomas. In this study, we therefore investigated whether elevated serum levels correlate with enhanced TGF-1 expression in human bladder tumours. mRNA levels of TGF-p1, -12 and -133 were reduced in bladder tumour tissue to 86%, 68% and 56%, respectively, of the levels in normal urothelium. On the other hand, TGF-1l protein levels were found to be higher in superficial tumours (T7-T,) (mean level of 0.153 ng mg-1) and in invasive TJ/3 tumours (mean level of 0.104 ng mg-') compared with normal urothelium (mean level of 0.065 ng mg-').Invasive T4 tumours, however, contained only low amounts of TGF-1l (mean level of 0.02 ng mg-').

show abstract

supporting

confidence: 60%

Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas

Eder

Stenzl²,

Hobisch³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…73,74 Several studies have shown that increased levels of circulating TGF-b1 were associated with cancer progression, occult and documented metastasis and biochemical progression in PCa patients. [74][75][76] However, other authors did not confirm such correlations. 77,78 Interleukin-6 (IL-6) is a cytokine with variable effects on immune and hematopoietic mechanisms.…”

Section: Urokinase Plasminogen Activation Systemmentioning

confidence: 90%

New circulating biomarkers for prostate cancer

Bensalah

Lotan

Karam

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

“…TGF-11 was shown to be the major secreted isoform in vitro, although in some cases TGF-133 was found; small amounts of TGF-[32 were specifically secreted by melanoma cells and not by benign melanocytes (Krasagakis et al, 1997 (Ivanovic et al, 1995;Tsushima et al, 1996) causatively involved in the impairment of the immune system in melanoma patients with advanced tumour dissemination. Indeed, several lines of evidence suggest a role for tumour-derived TGF-[3-mediated immunosuppression.…”

Section: Discussionmentioning

confidence: 99%

Elevated plasma levels of transforming growth factor (TGF)-β1 and TGF-β2 in patients with disseminated malignant melanoma

Krasagakis

Thölke²,

Farthmann³

et al. 1998

Br J Cancer

136

101

View full text Add to dashboard Cite

Summary Overexpression of transforming growth factor-4 isoforms (TGF-f1, -P2, -,B3) has been previously reported in human melanoma cell lines and tumours. The aim of the present study was to evaluate the plasma levels of TGF-f isoforms in melanoma patients. Significantly elevated levels of TGF-,1l (4.2 x the controls, P= 0.0094) and of TGF-,2 (1.5 x the controls, P= 0.012) but not of TGF-13 were measured in patients with disseminated but not locoregional melanoma. These results indicate systemic circulation of potentially immunosuppressive peptides of the TGF-P family in end-stage melanoma patients.

show abstract

Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer

Cited by 161 publications

References 11 publications

Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas

Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas

New circulating biomarkers for prostate cancer

Elevated plasma levels of transforming growth factor (TGF)-β1 and TGF-β2 in patients with disseminated malignant melanoma

Contact Info

Product

Resources

About